Iselin, NJ, November 12, 2009 – Pharmos Corporation (OTCBB: PARS.PK) today reported financial results for the third quarter and nine-month period ended September 30, 2009. Third Quarter Ended September 30, 2009 The Company recorded a net loss of $1.4 million, or $0.02 per share, for the third quarter 2009 compared to a net loss of $2.8 million, or $0.11 per share, in the third quarter 2008. […]
Iselin NJ, October 21, 2009 – Pharmos Corporation (OTCBB – PARS.PK); on September 14, 2009, Pharmos announced the results of its Phase 2b Dextofisopam trial for the treatment of diarrhea predominant and alternating diarrhea and constipation irritable bowel syndrome. While the results did not achieve statistical significance for the primary endpoint of overall adequate relief due to an unexpectedly high placebo response rate, the drug clearly […]
Primary Endpoint was not Achieved, but the 200 mg Treatment Group Demonstrated Activity and was Similar to Previous Phase 2a Successful Results Trial Evaluated Safety and Efficacy of Dextofisopam, a Novel First in-Class Compound Iselin NJ, September 14, 2009 – Pharmos Corporation (OTCBB: PARS.PK) announced today the results of its Phase 2b Dextofisopam clinical trial to evaluate safety and efficacy of the compound in irritable bowel […]
Iselin NJ, August 12, 2009 – Pharmos Corporation (OTCBB: PARS.PK) today reported financial results for the second quarter and six-month period ended June 30, 2009. Second Quarter Ended June 30, 2009 The Company recorded a net loss of $2.3 million, or $0.05 per share, for the second quarter 2009 compared to a net loss of $2.7 million, or $0.10 per share, in the second quarter 2008. […]
Iselin NJ, May 12, 2009 – Pharmos Corporation (OTCBB – PARS.PK) today reported results for the first quarter ended March 31, 2009. The Company recorded a net loss of $3.7 million, or $0.14 per share, for the first quarter 2009 compared to a net loss of $3.6 million, or $0.14 per share, in the first quarter 2008. Cash and short-term investments totaled $2.9 million at March […]
Iselin NJ, April 21, 2009 – Pharmos Corporation (OTCBB – PARS.PK) announced today that it has completed a private placement of common stock and warrants. At the closing, the Company issued 18,000,000 shares of common stock and warrants exercisable for an additional 18,000,000 shares of common stock for an aggregate purchase price of $1,800,000. The exercise price of the warrants, which have a five-year term, is […]
Iselin NJ, April 2, 2009 – Pharmos Corporation (OTCBB – PARS.PK) issued the following business update on the Dextofisopam Phase 2b trial and the status of financing operations. Dextofisopam Phase 2b trial As previously announced on March 4, 2009, Pharmos modified the size of the Dextofisopam Phase 2b trial for Irritable Bowel Syndrome IBS D+A to a minimum 300 patient trial. The trial is now essentially […]
Iselin NJ, March 6, 2009 – Pharmos Corporation (Nasdaq: PARS) announced today that it has received a Nasdaq Staff Determination that the company is not in compliance with the minimum $2,500,000 stockholders’ equity requirement for continued listing. Unless the company appeals the determination, its securities will be removed from listing and registration on The Nasdaq Stock Market. Pharmos does not intend to appeal the determination. The […]
Iselin NJ, March 4, 2009 – Pharmos Corporation (Nasdaq: PARS) announced today that it has completed a reevaluation of the size of the Phase 2b Dextofisopam trial for Irritable Bowel Syndrome IBS -D + A and has concluded that a smaller trial could achieve the objectives of the trial. As the Phase 2b trial is not going to be a registration /pivotal trial, the objectives that […]
Iselin NJ, February 27, 2009 – Pharmos Corporation (Nasdaq: PARS) today reported financial results for the fourth quarter and twelve-month period ended December 31, 2008. Fourth Quarter Ended December 31, 2008 The Company recorded a net loss of $1.0 million, or $0.04 per share, for the fourth quarter 2008 compared to a net loss of $2.7 million, or $0.11 per share, in the fourth quarter 2007. […]